Payment overview · 2025
General Payments
$712.35
39 reported records · 6 companies
Healthcare provider profile · identity verified
Anna Wong, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LOS ANGELES, CA · NPI 1194037481
Verified facts
What the public records show
CMS Open Payments records show Anna Wong, FNP received $712.35 in general payments during 2025 across 39 reported records.
ABBVIE INC. accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Kerendia, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 332 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexium by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Kerendia by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $243.40 | 34.2% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $170.93 | 24.0% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $147.44 | 20.7% | 10 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $89.34 | 12.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.41 | 6.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.83 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $712.35 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $243.40 | 10 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $170.93 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $147.44 | 10 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $139.92 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.41 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 69 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 332 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 149 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 114 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
69 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
114 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
332 | 73 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
149 | 34 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
68 | 66 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
133 | 102 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1127 | 262 |
| Atorvastatin Calcium | Atorvastatin Calcium | 676 | 157 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 581 | 134 |
| Vascepa | Icosapent Ethyl | 374 | 88 |
| Farxiga | Dapagliflozin Propanediol | 332 | 73 |
| Metformin Hcl | Metformin Hcl | 323 | 69 |
| Jardiance | Empagliflozin | 284 | 61 |
| Montelukast Sodium | Montelukast Sodium | 276 | 77 |
| Losartan Potassium | Losartan Potassium | 265 | 62 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 263 | 71 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 242 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 50 |
| Azelastine Hcl | Azelastine Hcl | 190 | 55 |
| Nebivolol Hcl | Nebivolol Hcl | 188 | 36 |
| Gabapentin | Gabapentin | 161 | 65 |
| Diclofenac Sodium | Diclofenac Sodium | 157 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 152 | 44 |
| Kerendia | Finerenone | 149 | 34 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 133 | 102 |
| Tradjenta | Linagliptin | 128 | 29 |
| Telmisartan | Telmisartan | 127 | 22 |
| Januvia | Sitagliptin Phosphate | 124 | 29 |
| Carvedilol | Carvedilol | 123 | 29 |
| Icosapent Ethyl | Icosapent Ethyl | 120 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 33 |
| Linzess | Linaclotide | 114 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 110 | 24 |
| Famotidine | Famotidine | 108 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 33 |
| Lidocaine | Lidocaine | 107 | 34 |
| Allopurinol | Allopurinol | 106 | 34 |
| Omeprazole | Omeprazole | 106 | 42 |
| Metformin Hcl Er | Metformin Hcl | 103 | 27 |
| Ezetimibe | Ezetimibe | 102 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 102 | 15 |
| Celecoxib | Celecoxib | 99 | 37 |
| Dexlansoprazole Dr | Dexlansoprazole | 96 | 20 |
| Hydrocortisone | Hydrocortisone | 92 | 31 |
| Rybelsus | Semaglutide | 92 | 24 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 87 | 38 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 81 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 79 | 32 |
| Fluocinonide | Fluocinonide | 78 | 33 |
| Amoxicillin | Amoxicillin | 77 | 57 |
| Prolia | Denosumab | 76 | 49 |
| Meclizine Hcl | Meclizine Hcl | 75 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 15 |
| Creon | Lipase/Protease/Amylase | 69 | 18 |
| Finasteride | Finasteride | 69 | 16 |
| Lisinopril | Lisinopril | 69 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 68 | 66 |
| Licart | Diclofenac Epolamine | 67 | 23 |
| Glipizide | Glipizide | 66 | 13 |
| Ibuprofen | Ibuprofen | 65 | 32 |
| Clonidine Hcl | Clonidine Hcl | 63 | 30 |
| Loperamide | Loperamide Hcl | 62 | 55 |
| Atenolol | Atenolol | 58 | 15 |
| Febuxostat | Febuxostat | 58 | 16 |
| Nifedipine Er | Nifedipine | 58 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 58 | 20 |
| Cequa | Cyclosporine | 57 | 20 |
| Ammonium Lactate | Ammonium Lactate | 56 | 27 |
| Furosemide | Furosemide | 54 | 23 |
| Single Use Swab | Alcohol Antiseptic Pads | 54 | 27 |
| Restasis | Cyclosporine | 53 | 20 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 50 | 50 |
| Ramelteon | Ramelteon | 49 | 13 |
| Alendronate Sodium | Alendronate Sodium | 47 | 12 |
| Fenofibrate | Fenofibrate,micronized | 47 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 12 |
| Vemlidy | Tenofovir Alafenamide | 46 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 45 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 22 |
| Glipizide Er | Glipizide | 45 | suppressed |
| Glimepiride | Glimepiride | 44 | 12 |
| Irbesartan | Irbesartan | 43 | suppressed |
| Ztlido | Lidocaine | 43 | 12 |
| Repaglinide | Repaglinide | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 37 |
| Naproxen | Naproxen | 41 | 29 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 11 |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Prednisone | Prednisone | 38 | 32 |
| Cephalexin | Cephalexin | 37 | 28 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 19 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 35 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 14 |
| Baclofen | Baclofen | 32 | suppressed |
| Eliquis | Apixaban | 32 | 13 |
| Ketoconazole | Ketoconazole | 32 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 31 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 31 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Cyclosporine | Cyclosporine | 29 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | 11 |
| Bepotastine Besilate | Bepotastine Besilate | 26 | suppressed |
| Horizant | Gabapentin Enacarbil | 26 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 22 |
| Methimazole | Methimazole | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 22 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 14 |
| Nexletol | Bempedoic Acid | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | 13 |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Ofloxacin | Ofloxacin | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 16 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 16 | suppressed |
| Nexium | Esomeprazole Magnesium | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Afrezza | Insulin Regular, Human | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | 12 |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Alphagan P | Brimonidine Tartrate | 11 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $712.35 · 39 records | ABBVIE INC. | CREON, FARXIGA, Kerendia, LINZESS, TRELEGY ELLIPTA, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error